Paul B. Manning, Director at Candel Therapeutics, Inc. (CADL), bought 36,000 shares at $7.36 ($265K) on 2021-07-27, disclosed to the SEC on 2021-07-29.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| VRCA | BUY | 2025-11-25 | $35.0M | — | Filing → |
| LQDA | SELL | 2025-09-02 | $37.9M | — | Filing → |
| TSHA | BUY | 2025-06-03 | $2.1M | — | Filing → |